{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Overall survival is defined as the amount of time from start of study therapy until death, or study completion. Participants entered at the MTD Dose level from the phase I portion of the study will also be included in this analysis","groups":[{"description":"Doxil, melphalan, bortezomib: Doxil®: IV over 30-60 min, Day 1 q28d\n\nMelphalan: IV over 30 min, Day 1 q28d\n\nVelcade®: IV bolus, Day 1, 4, 8, 11 q28d\n\nDose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2\n\nDose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2\n\nDose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2\n\nDose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2","id":"OG000","title":"Doxil® + Melphalan + Velcade (DMV)"}],"populationDescription":"Data not collected","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Survival (Phase 2)","type":"SECONDARY"}